Moderna is getting into the flu business
Moderna, which is racing to develop a vaccine for Covid-19, has set its sights on another lucrative opportunity: the multibillion-dollar business of trying to prevent seasonal influenza.
At its annual R&D presentation happening later today, Moderna will announce that it’s going to start developing vaccines for seasonal flu, as the Boston Globe reports. The company is betting its mRNA approach can create faster, more effective inoculations. Each year, flu vaccines tend to be between 40% and 60% effective, depending on which strain emerges. Moderna believes it can quickly develop better options, using the same technology that allowed it to produce a Covid-19 vaccine candidate in a matter of weeks.
It’s a major opportunity. Sanofi, which supplies about 40% of the world’s flu vaccines, makes roughly $2 billion a year doing so. But it’s a business that requires global scale generally reserved for major pharmaceutical companies. Moderna’s future in the field would likely depend on resounding success in Covid-19, which is by no means guaranteed, followed by a worldwide expansion.
At its annual R&D presentation happening later today, Moderna will announce that it’s going to start developing vaccines for seasonal flu, as the Boston Globe reports. The company is betting its mRNA approach can create faster, more effective inoculations. Each year, flu vaccines tend to be between 40% and 60% effective, depending on which strain emerges. Moderna believes it can quickly develop better options, using the same technology that allowed it to produce a Covid-19 vaccine candidate in a matter of weeks.
It’s a major opportunity. Sanofi, which supplies about 40% of the world’s flu vaccines, makes roughly $2 billion a year doing so. But it’s a business that requires global scale generally reserved for major pharmaceutical companies. Moderna’s future in the field would likely depend on resounding success in Covid-19, which is by no means guaranteed, followed by a worldwide expansion.
.png)
No hay comentarios:
Publicar un comentario